Patents by Inventor Daniel F. Egan

Daniel F. Egan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ULK1 inhibitors and methods using same
    Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • ULK1 inhibitors and methods using same
    Patent number: 10689397
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 23, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190284207
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: April 19, 2019
    Publication date: September 19, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190248806
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 15, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190152989
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • ULK1 inhibitors and methods using same
    Patent number: 10266549
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 23, 2019
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20170342088
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: August 25, 2015
    Publication date: November 30, 2017
    Applicants: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, YALE UNIVERSITY
    Inventors: REUBEN J. SHAW, DANIEL F. EGAN, NICHOLAS COSFORD, BENJAMIN TURK, MITCHELL VAMOS, DHANYA RAVEENDRA PANICKAR, MATTHEW CHUN, DOUG SHEFFLER
  • ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE
    Publication number: 20160289651
    Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.
    Type: Application
    Filed: February 24, 2016
    Publication date: October 6, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Reuben J. Shaw, Daniel F. Egan, Maria Mihaylova, David Shackelford
  • ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE
    Publication number: 20130040310
    Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.
    Type: Application
    Filed: December 15, 2010
    Publication date: February 14, 2013
    Applicant: Salk Institute for Biological Studies
    Inventors: Reuben Shaw, Daniel F. Egan, Maria Mihavlova, David Shackelford